Supplementary Figures 1-9 from ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer

Supplementary Figure 1. Progression free survival of patients with selected mutations. Supplementary Figure 2. H356Y does not activate estrogen signalling or alter fulvestrant sensitivity in combination with L536P. Supplementary Figure 3. Acquired ESR1 F404 mutations in patients treated with Fulvestrant. Supplementary Figure 4. Expression of individual ER target genes in RNAseq experiment. Supplementary Figure 5. Loss of F404L mutation in long-term culture of “E” mutant clones. Supplementary Figure 6. Response of D538G+F404L mutant models to elacestrant. Supplementary Figure 7. Response of D538G+F404L mutant models to camizestrant. Supplementary Figure 8. Response of D538G+F404L mutant models to 4OH tamoxifen. Supplementary Figure 9. Response of D538G+F404L mutant models to giredestrant.